Clinical response: mean score/change in global state: mean CGI‐II Global improvement score (high = poor) Short term (6 weeks) · people with treatment‐resistant schizophrenia
1 finding from 1 review
Global state: no improvement ‐ short term · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) changes global state: no improvement ‐ short term compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (very low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
CHLORPROMAZINE LOW DOSE (≤ 400 mg/day) probably leads to lower adverse effects: extrapyramidal symptoms (unspecified extrapyramidal… compared with MEDIUM DOSE (401 mg/day to 800 mg/day) (moderate certainty).
1 finding from 1 review
Severity of PTSD symptoms · Adults with co‐morbid PTSD and SMI
1 finding from 1 review
Mental state: 1a. General symptoms ‐ average change (PANSS, short term) · patients with schizophrenia
1 finding from 1 review
Mental state: 2c. Specific ‐ average change score for negative symptoms (PANSS ‐ negative short term) · patients with schizophrenia
1 finding from 1 review
Adverse effects: incidence of serious adverse effects. Movement disorders ‐ dyskinesia ‐short‐term · patients with schizophrenia
It is very uncertain whether chlorpromazine changes adverse effects: incidence of serious adverse effects. Movement… compared with clotiapine (very low certainty).
1 finding from 1 review
Intervention not reported
Service utilisation: hospital admission (short term) · patients with schizophrenia
The intervention showed no clear difference in service utilisation: hospital admission (short term) (low certainty).
1 finding from 1 review
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
YOGA probably leads to lower leaving the study early: short term compared with NON‐STANDARD CARE (moderate certainty).
1 finding from 1 review
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION may leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
WENDAN DECOCTION probably leads to lower adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms… compared with ANTIPSYCHOTIC DRUG (moderate certainty).
1 finding from 1 review
Use of Western medicine: Reduced dose of Western medicine (short term) · patients with schizophrenia
1 finding from 1 review
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC probably leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
WENDAN DECOCTION PLUS NORMAL DOSE ANTIPSYCHOTIC probably leads to lower adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · patients with schizophrenia
1 finding from 1 review
Use of Western medicine: Reduced dose of Western medicine (short term) · patients with schizophrenia
1 finding from 1 review
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC probably leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia
WENDAN DECOCTION PLUS LOW DOSE ANTIPSYCHOTIC probably leads to lower adverse effects: Movement disorders ‐ Extra Pyramidal Symptoms… compared with NORMAL DOSE ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review